Hops Scalable Vision Jet Fleet Expansion Unlocking High-Frequency Short-Haul Regional Travel Flyte’s Vision Jet-Powered Hops Platform Aims to Establish a New Standard in Regional Travel with Industry-Leading Safety, Speed, Efficiency and Affordability FORT MILL, S.C., March 25, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) and its wholly-owned subsidiary Fly Flyte, Inc. (“Flyte”), today announced the expansion of its Vision Jet-powered Hops platform, a scalable short-haul regional ...

Fleet Expansion Underway With Five Vision Jets Expected to Be Operating by Memorial Day Regional Aviation Platform Now Connects Entire East Coast Following Successful Soft Launch in Florida FORT MILL, S.C., March 16, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) today announced the official launch of Flyte Hops Florida, expanding Flyte’s regional aviation network from its original New York-based service to now providing multiple aircraft along the entire East Coast from Maine to Fl ...

Core Viewpoint - Catheter Precision, Inc. has announced significant balance sheet improvements through new institutional capital commitments, supporting the growth of its subsidiary Flyte and its expansion strategy in the regional aviation market [1][2][3]. Group 1: Growth Strategy and Capital Support - Flyte, a newly acquired subsidiary, is positioned to execute its expansion strategy with a fully funded growth plan supported by Catheter Precision [2]. - Recent strategic financings have been completed to support the transformation of the company and the expansion of the Flyte aviation platform, which also includes funding for medical device operations [2][3]. - The company believes that with access to significant institutional capital, Flyte is uniquely positioned to expand fleet operations and enter new markets [3][10]. Group 2: Market Opportunity and Operational Foundation - The regional air mobility sector is viewed as a major growth opportunity within the aviation industry, driven by increasing demand for faster regional transportation options [11]. - Flyte aims to address the growing demand for time-efficient regional air mobility, offering premium point-to-point travel between major metropolitan regions and underserved secondary markets [5][10]. - The operational foundation of Flyte allows for rapid fleet growth and expansion into additional high-demand regional markets [6][11]. Group 3: Fleet Expansion and Infrastructure - Flyte operates a growing fleet of certified aircraft and has established route infrastructure across key regional markets [9]. - The company is focused on scaling its aviation platform infrastructure and expanding its market presence across additional regional corridors [8][9]. - The acquisition of Flyte, combined with newly secured institutional capital, provides a foundation for a focused, high-growth aviation strategy while simplifying the company's balance sheet [7][10].

Core Insights - The acquisition of Flyte by Catheter Precision, Inc. (VTAK) transforms it from a minority investment into a wholly owned subsidiary, enhancing VTAK's position in the regional air mobility sector with a scalable, revenue-generating aviation platform [1][2][5] Group 1: Acquisition Details - VTAK has completed the acquisition of an 80.02% equity interest in Flyte, achieving 100% ownership of the AI-enabled regional aviation operator [1] - Flyte operates under FAA 14 CFR Part 135 certification, utilizing Cirrus Vision Jets for high-frequency, short-haul regional routes where commercial airline capacity is limited [3][4] Group 2: Financial Impact - Full ownership allows for the consolidation of Flyte's operations, assets, and financial results into VTAK's statements, providing direct exposure to operating performance and long-term value creation [4] - The acquisition is expected to enhance VTAK's long-term valuation profile by contributing consolidated revenues and asset backing, along with the potential for substantial operating leverage [6] Group 3: Strategic Positioning - The acquisition aligns with VTAK's strategy of investing in businesses with tangible assets and scalable infrastructure, supporting sustainable growth and long-term value creation [5][7] - Flyte's operational model emphasizes capital efficiency and high aircraft utilization, positioning it well for disciplined expansion in response to market demand [7][9] Group 4: Market Opportunities - Flyte operates in short-haul corridors targeted by future advanced air mobility and electric aircraft developers, generating real operating data and customer engagement while maintaining flexibility for future industry evolution [11][12] - The structure allows VTAK to engage in regional air mobility growth without relying on extended certification timelines, combining current revenue generation with future strategic options [12]

Core Insights - Catheter Precision, Inc. announced that its LockeT suture retention device will be featured during live procedural cases at the International Symposium of Left Atrial Appendage 2026 conference, highlighting its significance in the cardiac electrophysiology market [1] Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for the treatment of cardiac arrhythmias, emphasizing collaboration with physicians and continuous product advancement [6] Product Information - The LockeT device is designed to assist in wound closure after percutaneous venous punctures, classified as a Class 1 device registered with the FDA and has received CE Mark approval [5] Event Participation - The ISLAA meeting serves as a multi-specialty cardiovascular educational symposium, where leading physicians will manage the program, providing hands-on demonstrations and product education for electrophysiology fellows [2][3] - Catheter Precision will participate in these sessions, allowing fellows to experience the LockeT device and learn about its benefits, including cost reduction for hospitals and same-day discharge [3] Industry Recognition - The CEO of Catheter Precision, David Jenkins, expressed pride in the growing recognition of LockeT at prestigious industry events, emphasizing the importance of live clinical cases for validating the device's efficiency and cost-effectiveness [4]

Core Insights - Catheter Precision (NYSE: VTAK) announced a strategic divestiture of its non-core assets, specifically its atherectomy catheter technologies, to focus on its electrophysiology platform [2][3]. Strategic Shift - The divestiture aims to enhance capital efficiency and sharpen the company's focus on high-growth areas within cardiac electrophysiology [2][3]. - The transaction is expected to accelerate execution across the electrophysiology product portfolio while maintaining exposure to the future commercial success of the divested technologies [3]. Transaction Details - The deal includes an upfront cash payment of $15,000, a 5% equity stake in the acquiring company with anti-dilution protection, and a ten-year royalty payments agreement on net sales [4]. Stock Performance - VTAK shares are currently trading 21.1% below the 20-day simple moving average (SMA) and 31.7% below the 100-day SMA, indicating a bearish short-term trend [5]. - Over the past 12 months, shares have decreased by 75.82% and are near their 52-week lows [5]. - At the time of publication, shares were down 5.05% at $1.61, close to the 52-week low of $1.13 [7].

Core Viewpoint - Catheter Precision, Inc. has announced a definitive agreement to divest its atherectomy catheter technologies, enhancing capital efficiency and focusing on its high-growth electrophysiology platform [1][2]. Strategic Rationale - The transaction is expected to accelerate execution across the electrophysiology product portfolio while maintaining exposure to the future commercial success of the divested technologies [4]. Transaction Highlights - The company will receive an upfront cash payment of $15 million upon closing [7]. - It will retain a 5% equity stake in the acquiring company, with anti-dilution protection for up to $5 million of additional equity capital invested [7]. - A ten-year royalty payments agreement will be established, starting with a 1.5% baseline that increases to 3% on quarterly net sales exceeding $5 million [7]. - The transaction is designed to create potential long-term equity upside participation and recurring revenue through performance-based royalties [7]. Company Overview - Catheter Precision is a U.S.-based medical device company focused on advancing the treatment of cardiac arrhythmias through innovative electrophysiology technologies developed in collaboration with leading physicians [5].

Core Insights - Creatd, Inc. announced that Catheter Precision, Inc. has acquired a 20% equity interest in its subsidiary Fly Flyte, Inc. through a secondary purchase from an existing shareholder, aligning with Creatd's strategy of nurturing technology-enabled subsidiaries while maintaining operational independence [1] - The CEO of Creatd emphasized the company's commitment to building a portfolio of small-cap operating companies, aiming to address market gaps created by the contraction of middle markets over the last two decades [2] - Fly Flyte is currently operational, providing AI-enabled regional aviation services that enhance accessibility and convenience, leveraging certified aircraft and established routes for real-time revenue generation [2] Strategic Developments - The partnership with NYSE-listed VTAK expands Fly Flyte's investor network, enhancing its growth potential [4] - Creatd is actively pursuing multiple acquisition discussions to advance its portfolio strategy [4] - Fly Flyte is positioned to transform regional aviation through its focus on accessibility, convenience, and technology-driven operations [4] Company Overview - Creatd, Inc. focuses on acquiring and growing technology-driven companies in sectors such as aviation, media, and advisory services, utilizing a shared services model to enable efficient scaling and market reach [3]

Core Insights - Catheter Precision, Inc. has made a strategic minority investment in Fly Flyte, Inc., a regional aviation operator, to gain immediate exposure to a revenue-generating, asset-backed business in the air mobility sector [1][10] Investment Overview - The investment allows Catheter Precision to acquire a 19.98% equity ownership in Flyte, providing access to one of the fastest-growing segments of private aviation [7] - Flyte operates under FAA certification and is currently generating revenue with its fleet of Cirrus Vision Jets, which are equipped with advanced safety features [2][8] Strategic Positioning - Flyte is positioned to benefit from the anticipated future commercialization of electric vertical takeoff and landing (eVTOL) aircraft, operating in the same corridors targeted for future electric aircraft integration [5][6] - The company leverages certified aircraft and established infrastructure to generate active revenue and customer engagement, which is crucial for long-term capital investment [6][9] Operational Efficiency - Flyte employs AI-enabled optimization across various operational aspects, including routing, pricing, and dispatch, contributing to a capital-efficient growth model [8] - The company maintains a disciplined approach to expansion, targeting scalable revenue growth while preserving capital efficiency [4][11] Long-Term Value Creation - The investment reflects a broader strategy of Catheter Precision to deploy capital into businesses with scalable infrastructure and clear paths to long-term value creation [10][16] - Flyte's model is designed for disciplined execution and measured growth, positioning it well for the evolving regional air mobility landscape [11]

Core Viewpoint - Catheter Precision, Inc. has terminated its at-the-market equity offering program and secured a strategic financing transaction with institutional investors for up to $36.5 million to support accelerated growth [1][3]. Group 1: Financial Position and Strategy - The termination of the ATM equity offering program is aimed at strengthening the company's balance sheet and aligning with long-term institutional capital for value creation [1][3]. - The strategic financing enhances institutional investor confidence in the company's strategy and eliminates legacy financing overhang [3][7]. - The company has converted short-term notes to long-term by extending maturities to two and three years, significantly strengthening its balance sheet and liquidity [7]. Group 2: Growth Initiatives - The strategic institutional investment provides financial flexibility to advance key growth initiatives and scale multiple business opportunities [4][8]. - The company aims to expand its market presence and execution capabilities through this new capital [8].